nan

Nouscom | 13,768 followers on LinkedIn. Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients.
Nouscom’s clinical pipeline includes NOUS-209, an off-the-shelf cancer immunotherapy assessing the efficacy of the treatment in advanced MSI-H CRC patients in combination with pembrolizumab in randomized phase 2 trials. A Phase 1b study of NOUS-209 monotherapy in Lynch Syndrome Carriers with potential to ‘intercept cancer’ before it occurs is running in collaboration with the National Cancer Institute.

Additional jobs info: Clinical Project Manager (11,297 open jobs)